RECRUITING

Prospective Clinical Assessment Study in Children with Hypochondroplasia

Talk to us

Conditions

Hypochondroplasiaskeletal dysplasiaendochondral ossificationHCHshortened proximal limbsfibroblast growth factor receptor 3FGFR3endochondral bone formationdisproportionate short staturequality of lifedwarfismbone diseasesmusculoskeletal diseasesosteochondrodysplasiafunctional abilitiesannualized growth velocityannualized height velocitygrowthgenetic diseasescongenitalAHVAGV

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This is a long-term, multicenter, non-interventional study of children ages 2.5 to \<17 years with hypochondroplasia (HCH).

Official Title

Prospective Clinical Assessment Study in Children with Hypochondroplasia: ACCEL

Quick Facts

Study Start:2024-06-05
Study Completion:2026-10
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06410976

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:30 Months to 16 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:CHILD
Inclusion CriteriaExclusion Criteria
  1. Age 18 years or older
  2. Willing and able to provide informed consent
  3. Able to understand and follow study procedures
  4. Stable medical condition
  1. Pregnancy or breastfeeding
  2. Severe psychiatric disorders
  3. Active substance abuse
  4. Unstable medical conditions
  5. Inability to comply with study requirements

Contacts and Locations

Study Contact

QED Therapeutics, Inc
CONTACT
1-877-280-5655
medinfo@qedtx.com

Study Locations (Sites)

UCSF Benioff Children's Hospital
Oakland, California, 94609
United States
Childrens Hospital Colorado
Aurora, Colorado, 80045
United States
Children's National Hospital
Washington DC, District of Columbia, 20010
United States
Johns Hopkins School of Medicine
Baltimore, Maryland, 21287
United States
University of Missouri
Columbia, Missouri, 65201
United States
Vanderbilt University Medical Center
Nashville, Tennessee, 37232
United States
University of Wisconsin Madison - Waisman Center Bone Dysplasia Clinic
Madison, Wisconsin, 53705
United States

Collaborators and Investigators

Sponsor: QED Therapeutics, Inc.

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2024-06-05
Study Completion Date2026-10

Study Record Updates

Study Start Date2024-06-05
Study Completion Date2026-10

Terms related to this study

Keywords Provided by Researchers

  • skeletal dysplasia
  • endochondral ossification
  • hypochondroplasia
  • HCH
  • shortened proximal limbs
  • fibroblast growth factor receptor 3
  • FGFR3
  • endochondral bone formation
  • disproportionate short stature
  • quality of life
  • dwarfism
  • bone diseases
  • musculoskeletal diseases
  • osteochondrodysplasia
  • functional abilities
  • annualized growth velocity
  • annualized height velocity
  • growth
  • genetic diseases
  • congenital
  • AHV
  • AGV

Additional Relevant MeSH Terms

  • Hypochondroplasia